ABCL - AbCellera Biologics Inc. -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg · closes rebased to 100 at each year's first session
Ticker Details
AbCellera Biologics Inc.
IPO Date: December 11, 2020
Sector: Healthcare
Industry: Biotech
Market Cap: $4.16B
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.38 | 3.61%
Avg Daily Range (30 D): $0.42 | 3.39%
Avg Daily Range (90 D): $0.40 | 4.83%
Institutional Daily Volume
Avg Daily Volume: 2.82M
Avg Daily Volume (30 D): 4.73M
Avg Daily Volume (90 D): 6.5M
Trade Size
Avg Trade Size (Sh.): 171
Avg Trade Size (Sh.) (30 D): 128
Avg Trade Size (Sh.) (90 D): 157
Institutional Trades
Total Institutional Trades: 1,657
Avg Institutional Trade: $1.75M
Avg Institutional Trade (30 D): $1.87M
Avg Institutional Trade (90 D): $1.75M
Avg Institutional Trade Volume: .18M
Avg Institutional Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $1.97M
Avg Closing Trade (30 D): $3.22M
Avg Closing Trade (90 D): $2.48M
Avg Closing Volume: 208.27K
 
News
Aug 14, 2025 @ 11:23 AM
Prelude Cuts Q2 Losses and Costs 13%
Source: Jesterai
Jul 30, 2025 @ 5:00 PM
Global Antibody Discovery Market to Observe Stupen...
Source: Delveinsight
Jun 13, 2024 @ 9:40 AM
Down 57%, Is AbCellera Biologics a Buy on the Dip?...
Source: newsfeedback@fool.com (Cory Renauer)
May 8, 2024 @ 8:30 AM
AbCellera Biologics (ABCL) Q1 2024 Earnings Call T...
Source: newsfeedback@fool.com (Motley Fool Transcribing)
May 7, 2024 @ 10:05 PM
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, M...
Source: Zacks Equity Research
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $-.54 $-.18 $-.14
Diluted EPS $-.54 $-.18 $-.14
Revenue $66.17M $4.05M $8.32M
Gross Profit
Net Income / Loss $-164.66M $-55.43M $-43.17M
Operating Income / Loss $-225.16M $-62.78M $-57.52M
Cost of Revenue
Net Cash Flow $27.3M $43.23M $-51.45M
PE Ratio